When Sanofi picked up biotech Synthorx for a cool $2.5 billion this month, it paid a rich premium to enter an increasingly competitive immunotherapy field.
But in the face of stiff competition, sometimes a blow-away bid is what it takes to win the day.
Synthorx picked Sanofi out of a field of four suitors for IL-2 candidate THOR-707, ultimately nailing down a 172% premium on the biotech’s Dec. 5 closing price, according to an SEC filing. And Sanofi didn’t just survive a bidding war, but an eleventh-hour offer from a rival player, too.
In the biotech’s retelling of the deal, Sanofi and Synthorx’s courtship began in mid-October 2018 at the European Society for Medical Oncology meeting in Munich, where the companies discussed possible partnering opportunities for THOR-707 and pre-clinical IL-2 med THOR-809.
Synthorx, then still a private firm, had previously reached a confidentiality agreement with another drugmaker, dubbed Company B, before its discussions with Sanofi began.
After going public in December 2018, Synthorx then embarked on a nearly year-long coming-out party, meeting with a number of global drugmakers and eventually attracting two other suitors over the course of early 2019––Company A and Company C, Synthorx said. Some of that early interest focused on possible partnerships for THOR-809, a pre-clinical candidate to treat autoimmune diseases.
Sanofi, amid the blossoming bidding war—and after an in-person meeting in San Diego in July—offered up terms to Synthorx on Sept. 17 for a partnership on its clinical assets. It didn’t take long for Synthorx to reject them. Just a week later, the biotech told Sanofi the terms would need to be “clarified and improved.”
On Oct. 1, Synthorx likewise rejected a partnership offer from Company B, which pulled out of the running altogether Oct. 17. Sanofi then broke the seal on acquisition talks Nov. 25, offering $36 per share in cash––a 112% premium––to pick up the biotech outright.
Sanofi made clear to Synthorx that it was not interested in a “protracted process” and had a separate transaction in the works if its deal for Synthorx did not come to fruition by year’s end.
Synthorx bit — but only partly. Its board told adviser Centerview Partners to solicit buyout offers from all its suitors, which might have sped up the process. But it also told Sanofi to up its offer to $45 per share to stay competitive.
That was November 30. On Dec. 1, Company A entered the fray with a cash offer of $44 per share, or $41.50 in cash up front, plus possible $6 per share in milestones based on the company’s pipeline assets.
Sanofi came back December 2 with an offer of $41 per share contingent on Synthorx agreeing to a deal the very next day, given its own advanced discussions with another company.
Synthorx called Sanofi’s bluff on the deadline, informing them that they weren’t the highest bidder in the deal. Far from it, actually. Company A came forward on Dec. 3 with an re-upped offer of $47.75 per share at an equity value of $1.7 billion.
Sanofi took the lead soon after with an offer of $50.50 per share at a whopping 179% premium on the prior day’s closing price.
The same day, Company C opted to back out. For Company A it was a different story: Not wanting to lose the initiative, it responded with a $62 per share offer, or $2.1 billion.
But ultimately Sanofi’s final offer of $68 per share—a 172% premium on that prior day’s closing price—would win the day.
At 3:13 p.m. Dec. 6, Sanofi handed over its final offer, saying it needed an answer by 8 p.m. that day or it would walk. Synthorx’s board, sensing that it had reached its deadline, agreed to the deal that afternoon.
In one final twist, though, Company A made an unsolicited offer for Synthorx at $70 per share two days later, but it was too late. Synthorx signed the merger agreement with Sanofi and planned a news release the next morning.
Ultimately, Synthorx reasoned that going it alone with its IL-2 drugs’ clinical testing and launches left too much uncertainty on the table, the company said.
“(The board) concluded that the risks, uncertainties, restrictions and potentially negative factors … were outweighed by the potential benefits,” Synthorx said.
In return for the outlay, Sanofi is getting a drug that its R&D chief, John Reed, thinks could “become a foundation of the next generation of immuno-oncology combination therapies.”
“By selectively expanding the numbers of effector T-cells and natural killer cells in the body, THOR-707 can be combined with our current oncology medicines and our emerging pipeline of immuno-modulatory agents for treating cancer,” Reed said in a statement.
By Kyle Blankenship
Source: Fierce Pharma
AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey. The leading data and analytics company’s report, “The State of the Biopharmaceutical Industry – 2025,” highlights AI’s potential to boost productivity and cut costs in the coming year.
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as atopic dermatitis, asthma, and COPD.
While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as the first closed-loop therapy approach—allowing for self-adjusting neuromodulation in real time to help control the condition’s motor symptoms.
